Michiels JJ. Myeloproliferative and thrombotic burden and treatment outcome of thrombocythemia and polycythemia patients. World J Crit Care Med 2015; 4(3): 230-239 [PMID: 26261774 DOI: 10.5492/wjccm.v4.i3.230]
Corresponding Author of This Article
Jan Jacques Michiels, MD, PhD, Multidisciplinary Internist, International Collaborations and Research on Myeloproliferative Neoplasms (ICAR.MPN) and Goodheart Institute and Foundation in Nature Medicine and Health, Erasmus Tower, Veenmos 13, 3069 AT Rotterdam, The Netherlands. goodheartcenter@upcmail.nl
Research Domain of This Article
Allergy
Article-Type of This Article
Minireviews
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
World J Crit Care Med. Aug 4, 2015; 4(3): 230-239 Published online Aug 4, 2015. doi: 10.5492/wjccm.v4.i3.230
Myeloproliferative and thrombotic burden and treatment outcome of thrombocythemia and polycythemia patients
Jan Jacques Michiels
Jan Jacques Michiels, International Collaborations and Research on Myeloproliferative Neoplasms (ICAR.MPN) and Goodheart Institute and Foundation in Nature Medicine and Health, 3069 AT Rotterdam, The Netherlands
Author contributions: Michiels JJ solely contributed to this paper.
Conflict-of-interest statement: The author declares no confict of interest.
Open-Access: This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Correspondence to: Jan Jacques Michiels, MD, PhD, Multidisciplinary Internist, International Collaborations and Research on Myeloproliferative Neoplasms (ICAR.MPN) and Goodheart Institute and Foundation in Nature Medicine and Health, Erasmus Tower, Veenmos 13, 3069 AT Rotterdam, The Netherlands. goodheartcenter@upcmail.nl
Telephone: +31-62-6970534
Received: March 3, 2015 Peer-review started: March 4, 2015 First decision: April 10, 2015 Revised: June 10, 2015 Accepted: July 11, 2015 Article in press: July 14, 2015 Published online: August 4, 2015
Core Tip
Core tip: Spontaneous endogenous erythroid colony formation and low serum erythropoietin (EPO) levels are highly specific for JAK2V617F mutated essential thrombocythemia (ET), prodromal polycythemia vera (PV), masked PV and classical PV. The quantitation of JAK2V617F mutation allele burden plays a key-role in the diagnostic work-up and staging of ET, PV and MF patients. The JAK2V617F mutation allele burden in heterozygous mutated ET is low but high in combined heterozygous - homozygous or homozygous mutated PV. The combined use of JAK2V617F mutation load, spleen size and pretreatment bone marrow biopsy are of major prognostic significance and therapeutic importance in ET and PV patients. Large Prospective Unmet Need studies are warranted to delineate the natural history and outcome of targeted treatment in MPN patients of various molecular etiology during long-term or life long follow-up.
